Prevention of concanavalin A-induced mice hepatitis by molsidomine.
Molsidomine is effective in reducing portal hypertension in cirrhosis, but its effect on hepatitis is not known. In the present study, the effect of molsidomine on hepatitis was examined using mouse concanavalin A (Con A)-induced hepatitis and mouse anti-Fas antibody-induced hepatitis. Treatment of mice with Con A caused elevation of plasma alanine aminotransferase (ALT) at 8 and 24 h (n=4). Pretreatment of mice with molsidomine (3, 10, 30 and 100 mg/kg, i.p.) prevented Con A-induced hepatitis. Treatment of mice with anti-Fas antibody (150 microg/kg, i.v.) caused elevation of plasma ALT at 3.5 h. Pretreatment mice with molsidomine (10 mg/kg, i.p.) showed only 47% inhibition of anti-Fas antibody caused elevation of plasma ALT. The present results showed effectiveness of molsidomine in preventing Con A-induced mice hepatitis.
Okamoto
T
T
Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama 341-0005, Japan.
Masuda
Y
Y
Kawasaki
T
T
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control*; D003208:Concanavalin A / Q000633:toxicity*; D004195:Disease Models, Animal; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008981:Molsidomine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D019014:fas Receptor / Q000276:immunology
D000906:Antibodies; D014665:Vasodilator Agents; D019014:fas Receptor; D003208:Concanavalin A; D008981:Molsidomine; D000410:Alanine Transaminase